JP2021507924A - 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 - Google Patents

主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 Download PDF

Info

Publication number
JP2021507924A
JP2021507924A JP2020535008A JP2020535008A JP2021507924A JP 2021507924 A JP2021507924 A JP 2021507924A JP 2020535008 A JP2020535008 A JP 2020535008A JP 2020535008 A JP2020535008 A JP 2020535008A JP 2021507924 A JP2021507924 A JP 2021507924A
Authority
JP
Japan
Prior art keywords
hla
mhc
nucleic acid
cancer
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020535008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021507924A5 (https=
Inventor
サウサン ユーセフ，
サウサン ユーセフ，
ジェイコブ グランヴィル，
ジェイコブ グランヴィル，
Original Assignee
ディストリビューテッド バイオ， インコーポレイテッド
ディストリビューテッド バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディストリビューテッド バイオ， インコーポレイテッド, ディストリビューテッド バイオ， インコーポレイテッド filed Critical ディストリビューテッド バイオ， インコーポレイテッド
Publication of JP2021507924A publication Critical patent/JP2021507924A/ja
Publication of JP2021507924A5 publication Critical patent/JP2021507924A5/ja
Priority to JP2024031183A priority Critical patent/JP2024051157A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2020535008A 2017-12-22 2018-12-21 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 Pending JP2021507924A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024031183A JP2024051157A (ja) 2017-12-22 2024-03-01 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609589P 2017-12-22 2017-12-22
US62/609,589 2017-12-22
PCT/US2018/067380 WO2019126799A1 (en) 2017-12-22 2018-12-21 Major histocompatibility complex (mhc) compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024031183A Division JP2024051157A (ja) 2017-12-22 2024-03-01 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2021507924A true JP2021507924A (ja) 2021-02-25
JP2021507924A5 JP2021507924A5 (https=) 2021-12-16

Family

ID=66993888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020535008A Pending JP2021507924A (ja) 2017-12-22 2018-12-21 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法
JP2024031183A Pending JP2024051157A (ja) 2017-12-22 2024-03-01 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024031183A Pending JP2024051157A (ja) 2017-12-22 2024-03-01 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法

Country Status (4)

Country Link
US (1) US20210060126A1 (https=)
EP (1) EP3727467A4 (https=)
JP (2) JP2021507924A (https=)
WO (1) WO2019126799A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
JP7555822B2 (ja) 2018-04-19 2024-09-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア ゲノム編集のための組成物および方法
WO2021063340A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途
WO2022192701A1 (en) * 2021-03-12 2022-09-15 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074904B2 (en) * 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
EP0995798A1 (en) * 1998-10-24 2000-04-26 Novimmune Sa Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2002068614A2 (en) * 2001-02-26 2002-09-06 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
GB0109114D0 (en) * 2001-04-11 2001-05-30 King S College London Stimulation of the immune system
WO2006081629A1 (en) * 2005-02-04 2006-08-10 Stem Cell Australia Pty Ltd Adenoviral vectors comprising a nucleic acid encoding a mhc class i molecule and the use of such vectors in cancer therapy.
US8491913B2 (en) * 2009-03-07 2013-07-23 Oregon Health & Science University Compositions and methods using recombinant MHC molecules for the treatment of stroke
WO2012145384A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
US20160186208A1 (en) * 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
CN106459990B (zh) * 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
CN108026154B (zh) * 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
EP3402901A1 (en) * 2016-01-11 2018-11-21 Dixon, Janette Methods for determining tumour phenotypes
EP3419657A4 (en) * 2016-02-25 2019-11-06 Briacell Therapeutics Corp. CELLULAR CANCER VACCINES AND METHOD FOR SELECTION THEREOF
US20170321285A1 (en) * 2016-05-03 2017-11-09 The Texas A&M University System Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
EP3452101A2 (en) * 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NABEL, G. J. ET AL.: "Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility c", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 26, JPN6022051754, 1996, pages 15388 - 15393, ISSN: 0005307665 *
和田 聡, 玉田 耕治: "免疫療法の組み合わせ治療", 肝胆膵, vol. 第73巻, 第3号, JPN6022051757, 2016, pages 337 - 346, ISSN: 0005142024 *
山口 佳之, 峠 哲哉: "消化器癌に対する免疫遺伝子治療の現況", G.I.RESEARCH, vol. 第8巻, 第6号, JPN6022051751, 2000, pages 423 - 428, ISSN: 0005307664 *
鳥越 俊彦, 針生 寛之: "癌転移と免疫逃避", 医学のあゆみ, vol. 第206巻, 第4号, JPN6022051756, 2003, pages 256 - 260, ISSN: 0005142023 *

Also Published As

Publication number Publication date
EP3727467A4 (en) 2021-12-01
US20210060126A1 (en) 2021-03-04
JP2024051157A (ja) 2024-04-10
EP3727467A1 (en) 2020-10-28
WO2019126799A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
Hu et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
JP2024051157A (ja) 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法
US20250228945A1 (en) Neoantigens and uses thereof
JP7158483B2 (ja) 人工抗原提示細胞および使用方法
US12533409B2 (en) Compositions and methods for targeting mutant RAS
US11793867B2 (en) Neoantigens and uses thereof
JP2021527655A (ja) ネオ抗原およびそれらの使用
JP2017533702A (ja) 生体分子の免疫細胞への送達
TW201814041A (zh) 用於病毒專一性t細胞之活化及增生的平台
KR20170121178A (ko) 보편적인 살해 t-세포
Margolin et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy
TW201736594A (zh) 抗原特異性ｔｃｒ的新生成
JP2019524773A (ja) 樹状細胞のトランスフェクション及びその方法
US20250186586A1 (en) Methods of isolating and enhancing populations of tumor-reactive lymphocytes
US12370256B2 (en) Activation of resident memory T cells for the treatment of cancer
EP4293041A1 (en) Amplification enhancer and use thereof
Pai et al. Nasopharyngeal carcinoma‐associated Epstein–Barr virus‐encoded oncogene latent membrane protein 1 potentiates regulatory T‐cell function
BR112021005596A2 (pt) métodos de tratamento
JP2022552197A (ja) 自己細胞療法で免疫療法の非応答者を治療する方法
ES2827599A1 (es) Celulas madre mesenquimales para ser usadas como vehiculos de agentes terapeuticos
Yamada HLA class I antigen-processing machinery in cancer
WO2025083147A1 (en) Methods for analyzing immune responses and antigen profiling
EP4609202A2 (en) T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof
Salvato et al. T-Cell-Mediated Killing in Glioblastoma Organoids induced by Adenoviral Delivery of the CIITA Transgene
WO2025250534A1 (en) T cell targets for tuberculosis vaccines

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20210805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211026

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240419